Sidley represented global private equity firm Permira and its portfolio company Neuraxpharm on Neuraxpharm’s successful €925 million Term Loan B refinancing.
Neuraxpharm is one of Europe’s leading specialty pharmaceutical companies and has been at the forefront of the treatment of central nervous system (CNS) disorders for 40 years. The company’s deep expertise and commitment to innovation have positioned it as a trusted name in the research, development, and commercialization of CNS therapies across Europe.
The cross-border Sidley team was led by Global Finance partners Jay Sadanandan and Ben Wright, with key support from counsel Carry Chen and managing associate Phil Cerny. The wider cross-office and cross-practice team included partner Dr. Markus Feil, managing associate Christian Axhausen, and associate Alissia Opitz (Global Finance); and partner Steve Quinn and associate Ryan Power (Tax).
